(ARFORMOTEROL TARTRATE) INHALATION SOLUTION IN PEOPLE WITH MODERATE
Sunovion Pharmaceuticals Inc. (Sunovion) today announced that new analyses of clinical and health outcomes data for Brovana® (arformoterol tartrate) Inhalation Solution will be presented at the 2016 American Thoracic Society International Conference (ATS 2016), taking place May 13-18, 2016 in San Francisco, Calif. The company will present post-hoc analyses using data from a long-term safety study evaluating BROVANA use in people with moderate-to-severe chronic obstructive pulmonary disease (COPD). Results from a prospective health outcomes study assessing the prevalence of low peak inspiratory flow rate among real world COPD patients will also be presented at the meeting.Arformoterol tartrate powder
“COPD is a chronic and progressive disease affecting more than 15 million adults in the U.S. and is the third leading cause of death in the U.S.,” said Krithika Rajagopalan, Vice President, Head of Global Health Economics and Outcomes Research, Sunovion. “COPD exacerbations adversely impact a person’s quality of life, and also impose a substantial economic burden on the health system. Our aim is to provide treatments that can improve health outcomes for the COPD community, and the data being presented at ATS showcases Sunovion’s continued commitment to providing safe and effective treatment options for people with COPD.”
BROVANA Health Economics and Outcomes Research (HEOR) Data Presented at ATS:
Health-Related Quality of Life Among Patients Who Experienced Prior COPD-Related Exacerbations: Post Hoc Analysis of a 52-Week Randomized Placebo-Controlled Trial of Nebulized Arformoterol Tartrate – Poster #A6833, Board P63; Wednesday, May 18, 2016, 11:00 a.m. – 12:45 p.m., at Area A, Hall D (Lower Level), North Building, Moscone Center.
Chronic Obstructive Pulmonary Disease (COPD) - Related Hospitalizations by Health Status Response Among Patients Receiving Arformoterol Tartrate or Placebo: Post Hoc Analyses from a 52-Week Randomized, Controlled Study – Poster #A1122, Board 1017; Sunday, May 15, 2016, 9:00 a.m. – 11:00 a.m., at Room 3024 (3rd Level), West Building, Moscone Center.
“COPD is a chronic and progressive disease affecting more than 15 million adults in the U.S. and is the third leading cause of death in the U.S.,” said Krithika Rajagopalan, Vice President, Head of Global Health Economics and Outcomes Research, Sunovion. “COPD exacerbations adversely impact a person’s quality of life, and also impose a substantial economic burden on the health system. Our aim is to provide treatments that can improve health outcomes for the COPD community, and the data being presented at ATS showcases Sunovion’s continued commitment to providing safe and effective treatment options for people with COPD.”
BROVANA Health Economics and Outcomes Research (HEOR) Data Presented at ATS:
Health-Related Quality of Life Among Patients Who Experienced Prior COPD-Related Exacerbations: Post Hoc Analysis of a 52-Week Randomized Placebo-Controlled Trial of Nebulized Arformoterol Tartrate – Poster #A6833, Board P63; Wednesday, May 18, 2016, 11:00 a.m. – 12:45 p.m., at Area A, Hall D (Lower Level), North Building, Moscone Center.
Chronic Obstructive Pulmonary Disease (COPD) - Related Hospitalizations by Health Status Response Among Patients Receiving Arformoterol Tartrate or Placebo: Post Hoc Analyses from a 52-Week Randomized, Controlled Study – Poster #A1122, Board 1017; Sunday, May 15, 2016, 9:00 a.m. – 11:00 a.m., at Room 3024 (3rd Level), West Building, Moscone Center.
Replies